Quantcast
Last updated on April 18, 2014 at 13:58 EDT

Latest SLE Stories

0fd70a7f53fd8fce134869ca96e1c6b11
2009-07-23 09:25:00

Psychopharmaceutical use has risen over recent years. This is fact, but what is not clear is the reason why. Researchers from four Madrid-based health centers have shown that family conflict is not a significant factor. However, the results published in the journal Atenci³n Primaria are striking: in Spain, 24% of women take antidepressants and more than 30% take tranquilizers."The use of psychopharmaceuticals is often related to family or work-related problems. We wanted to see if there...

2009-07-19 23:01:00

ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and...

2009-06-12 09:58:58

Copenhagen, Denmark, Friday 12 June 2009: 92.8% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Logistic regression analysis revealed that depression was the most significant factor shown to affect QoL (p=0.015; OR=0.18;...

2009-06-11 10:21:25

 DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus (SLE), according to a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.SLE is a complex, chronic autoimmune disease...

2009-06-11 06:00:00

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...

2009-05-01 10:14:38

The sense of smell is a complex process of the central nervous system that involves specific areas of the brain. In fact, olfactory dysfunction is seen in various central nervous system disorders that involve immune-mediated mechanisms, such as Parkinson's disease, schizophrenia, Alzheimer's disease and multiple sclerosis. Systemic lupus erythematosus (SLE) is an autoimmune disease that sometimes involves the central nervous system in a condition known as neuropsychiatric SLE (NPSLE)....

2009-04-07 14:13:16

Study found use of oral contraceptives was associated with an increased risk of SLE, particularly among women who had recently started taking them The ratio of women to men with the autoimmune disease systemic lupus erythematosus (SLE) is nine to one and the incidence increases after puberty. Hormones secreted by the body are therefore believed to play an important role in the origins of the disease. A new large, population-based observational study found that the use of oral contraceptives...

2009-01-21 16:13:21

Mice from a strain that ordinarily develops systemic lupus erythematosus (SLE), but bred with a deficiency in receptor for the protein Interleukin 21, stayed healthy and exhibited none of the symptoms of the disease, researchers at The Jackson Laboratory and National Institutes of Health report. SLE is an autoimmune disease, with symptoms of varying severity including include painful or swollen joints, unexplained fever and extreme fatigue. An estimated 2 million Americans --nine out of 10 of...

2008-10-28 09:00:07

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*. In a completed Phase Ib trial twelve patients have been treated for 84 days at various dose levels of ABR-215757. The maximum tolerable dose (MTD) for ABR-215757 was defined as 4.5 mg/day. The overall safety profile throughout the...

2008-08-27 09:00:23

ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. (Logo:...